| Literature DB >> 16621178 |
V Raúl Gómez-Román1, George J Grimes, Gopal K Potti, Bo Peng, Thorsten Demberg, Luisa Gravlin, James Treece, Ranajit Pal, Eun Mi Lee, W Gregory Alvord, Phillip D Markham, Marjorie Robert-Guroff.
Abstract
Although replication-competent adenovirus (Ad) vectors are promising in AIDS vaccine design, their safety in immune compromised hosts is unknown. To initially address this question, enteric-coated tablets containing a replicating Ad vector were orally administered to SHIV- and SIV-infected rhesus macaques with normal, intermediate or low CD4 T cell counts and stable disease. The vector was detected within a week after tablet administration in stools of all animals but not in nasal secretions, indicating no spread of virus to the upper respiratory tract. CD4 T cell counts and viral loads remained stable in all animals and no signs of fever, weight loss, or other clinical symptoms of Ad-induced disease were observed during 10 weeks of follow-up. Oral delivery of the replicating Ad vector was safe and well tolerated by SHIV- and SIV-infected hosts. Oral enteric-coated tablets may prove safe for administering replicating Ad-vectored vaccines in areas with high HIV prevalence.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16621178 DOI: 10.1016/j.vaccine.2006.03.048
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641